Compare Navan Inc. Class A Common Stock (NAVN) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Navan Inc. Class A Common Stock vs Regeneron Pharmaceuticals Inc — how do they compare? Navan Inc. Class A Common Stock trades at $23.64 (market cap $6.01B), while Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 12.7× Navan Inc. Class A Common Stock's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Navan Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Navan Inc. Class A Common Stock for 1 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| NAVN | REGN | |
|---|---|---|
Market Cap | $6.01B | $76.14B |
Volume | 2,990,425 | 500,239 |
Sector | Technology | Health |
52-Week High | $30.58 | $852.03 |
52-Week Low | $8.51 | $557.73 |
Typical Hold Time | 1 Days | 107 Days |
Enterprise Value | $5.36B | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron Pharmaceuticals (REGN) trades at $739.57, down 0.34% with a bearish technical signal. The company maintains strong fundamentals with a 27.86% net income margin and consistent earnings beats. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront payments and milestone potential. Cash flow improved significantly in 2025 with $635 million net cash flow versus negative flows in prior years.
The stock presents a compelling investment case with strong profitability, positive analyst sentiment (69% buy ratings), and a $849.84 consensus price target offering 15% upside. Key risks include competitive pressures in ophthalmology drugs and reliance on key partnerships. The expanded Sanofi collaboration and promising clinical pipeline provide catalysts for growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Navan Inc. Class A Common Stock
Navan provides an AI-powered platform for business travel, payments, and expense management. Its tools support trip booking, policy controls, payment processing, expense reconciliation, and reporting.
Read more on NAVN →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
